TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring groundbreaking thrombolytic treatment to patients

Our portfolio company Targed Biopharmaceuticals raised Series A financing of € 39 million to develop improved treatments for thrombotic diseases. The financing was co-led by Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures, and joined by existing investors First, Curie Capital and UHSF.   Congratulations to

Utrecht Health Seed Fund’s first anniversary!

Before we knew, we’re celebrating Utrecht Health Seed Fund’s first anniversary! And what a year it has been. We can’t express how proud we are of our exceptional portfolio companies and the talented entrepreneurs and scientists driving these ventures: – TargED Biopharmaceuticals is developing a next generation clot-busting drug with

SentryX closes €3.2M seed funding round for the development of next generation pain relief therapeutics

We are delighted with the new investment in SentryX, a next generation, innovative pain relief therapy platform, focusing on orthopedic surgical post-procedural pain. Press release: June 9, 2021 – Utrecht, the Netherlands SentryX, a spin-off of the University Medical Center Utrecht (the Netherlands) today announced that it raised €3.2M in seed funding

TargED Biopharmaceuticals appoints Ludo Haazen, M.D. as Chief Medical Officer

TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, today announced the appointment of Ludo Haazen as Chief Medical Officer (CMO). Kristof Vercruysse, CEO of TargED commented: “We are delighted that Ludo is joining our team as CMO. In Ludo, we found the ideal candidate to support the

NTrans Technologies closes Series A investment to accelerate development of gene editing therapy

We’re excited to be investing in NTrans Technologies BV, a gene editing therapy company focusing on Duchenne Muscular Dystrophy, together with Essential Ventures, BOP Capital and Starfish Innovations. May 27, 2021 Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment

Moveshelf closes seed investment to accelerate digital transformation of diagnosis and care for movement disorders

We proudly announce UHSF’s second investment, in Moveshelf, together with Locapes Investment Fund. Moveshelf is a digital health company with a unique platform for clinical movement analysis. We look forward to working with their talented team! Please find the press release below: March 2nd, 2021, Utrecht, The Netherlands   Moveshelf, a

Interview with the TargED team and learn more about this exciting venture and its team!

In November 2020, TargED Biopharmaceuticals from Utrecht, The Netherlands, announced that they closed a seed investment round, and agreed on a public-private partnership with the UMC Utrecht.  For the Utrecht Health Seed Fund, this marked their first closing since opening the fund for investments in April 2020. TargED’s team has

TargED receives NWO Take-Off 2

Congratulations to the team of our portfolio company TargED Biopharmaceuticals, as they have been awarded a Take-Off 2 grant from NWO (the Dutch National Science Organization)!

Nieuws

New Utrecht-based fund investing in Life Science & Health start-ups

The Utrecht Health Seed Fund (UHSF) officially launched at…

Portal Utrecht Health Seed Fund open

On March 24 the portal of the Utrecht Health Seed Fund was opened. Despite,…

Utrecht Health Seed Fund launced

On March 24, 2020 a new investment fund will be launched - the…

Utrecht Health Seed Fund

The Utrecht Health Seed Fund (UHSF) is a joint initiative established…